Atai Life Sciences acquires exclusive rights to Psilera’s DMT patent portfolio
Atai Life Sciences has taken a strategic step in expanding its position in psychedelic medicine by securing exclusive rights to Psilera Inc.’s DMT patent portfolio. ... Read More
Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant ... Read More
Strides Pharma Science gets FDA approval for Fluoxetine Tablets for depressive disorders
Strides Pharma Science Limited (Strides) has made a notable advancement in the field of mental health treatment by securing approval from the United States Food ... Read More
Zydus Lifesciences gains FDA aproval for Chlorpromazine Hydrochloride Injection
In a notable development for the pharmaceutical industry, Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has received final approval from the United States ... Read More